JP2014510746A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510746A5 JP2014510746A5 JP2014501719A JP2014501719A JP2014510746A5 JP 2014510746 A5 JP2014510746 A5 JP 2014510746A5 JP 2014501719 A JP2014501719 A JP 2014501719A JP 2014501719 A JP2014501719 A JP 2014501719A JP 2014510746 A5 JP2014510746 A5 JP 2014510746A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- compound according
- pharmaceutical composition
- hcv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000031886 HIV Infections Diseases 0.000 claims description 3
- 208000037357 HIV infectious disease Diseases 0.000 claims description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000036142 Viral infection Diseases 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims 2
- 230000001861 immunosuppressant effect Effects 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 229930194542 Keto Natural products 0.000 claims 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- -1 aldehyde macrocycle Chemical class 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000000468 ketone group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002829 reductive effect Effects 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000000134 cyclophilin inhibitor Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000023611 glucuronidation Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229930185087 sanglifehrin Natural products 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OLROWHGDTNFZBH-XEMWPYQTSA-N Alisporivir Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(CC)C(=O)[C@@H](C)N(C)C1=O OLROWHGDTNFZBH-XEMWPYQTSA-N 0.000 description 1
- LBKDOKHAKPIWCL-NSVPLCITSA-N CC(C)[C@@H](C(N[C@](C1)(C1C(CC(O)=C1)C=C1F)C(N(CCC1)N[C@@H]1C(O[C@@H](C/C=C/C=C/[C@@H]([C@H](C)[C@H]([C@H]1CCC(C)=O)O)O)/C(/C)=C/C=O)=O)=O)=O)NC1=O Chemical compound CC(C)[C@@H](C(N[C@](C1)(C1C(CC(O)=C1)C=C1F)C(N(CCC1)N[C@@H]1C(O[C@@H](C/C=C/C=C/[C@@H]([C@H](C)[C@H]([C@H]1CCC(C)=O)O)O)/C(/C)=C/C=O)=O)=O)=O)NC1=O LBKDOKHAKPIWCL-NSVPLCITSA-N 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108010058359 alisporivir Proteins 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 208000027119 bilirubin metabolic disease Diseases 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 208000036796 hyperbilirubinemia Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1105293.3A GB201105293D0 (en) | 2011-03-29 | 2011-03-29 | Novel compounds and methods for their production |
| GB1105293.3 | 2011-03-29 | ||
| GBGB1113629.8A GB201113629D0 (en) | 2011-08-08 | 2011-08-08 | Novel compounds and methods for their production |
| GB1113629.8 | 2011-08-08 | ||
| GBGB1202060.8A GB201202060D0 (en) | 2012-02-07 | 2012-02-07 | Novel compounds and methods for their production |
| GB1202060.8 | 2012-02-07 | ||
| PCT/GB2012/050700 WO2012131371A1 (en) | 2011-03-29 | 2012-03-29 | Macrocyclic compound and methods for its production |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014510746A JP2014510746A (ja) | 2014-05-01 |
| JP2014510746A5 true JP2014510746A5 (enrdf_load_stackoverflow) | 2015-05-14 |
| JP6118792B2 JP6118792B2 (ja) | 2017-04-26 |
Family
ID=46001313
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014501720A Active JP6118793B2 (ja) | 2011-03-29 | 2012-03-29 | マクロ環状化合物及びそれらの製造方法 |
| JP2014501719A Expired - Fee Related JP6118792B2 (ja) | 2011-03-29 | 2012-03-29 | マクロ環状化合物及びその製造方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014501720A Active JP6118793B2 (ja) | 2011-03-29 | 2012-03-29 | マクロ環状化合物及びそれらの製造方法 |
Country Status (29)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2788761C (en) | 2010-02-09 | 2018-05-29 | Biotica Technology Limited | Sanglifehrin based compounds useful for treating viral infection caused by hcv, hbv or hiv |
| JO3063B1 (ar) * | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | مركب مبتكر وطرق لانتاجه |
| CN103130734A (zh) * | 2011-12-01 | 2013-06-05 | 上海药明康德新药开发有限公司 | 一种合成1,2-吗啉盐酸盐的方法 |
| CN105695541B (zh) * | 2016-03-10 | 2019-03-15 | 苏州华赛生物工程技术有限公司 | 一种抗生素nvp018中间体的分离纯化方法 |
| KR20180036522A (ko) * | 2016-09-30 | 2018-04-09 | (주)나노믹스 | 스틸벤 유도체 및 그 제조 방법 |
| CN110062626A (zh) * | 2016-11-18 | 2019-07-26 | 纽维制药有限公司 | sanglifehrin大环类似物作为抗癌化合物的用途 |
| CN112410353B (zh) * | 2019-08-23 | 2023-01-24 | 上海医药工业研究院 | 一种fkbS基因、含其的基因工程菌及其制备方法和用途 |
| CN115894606A (zh) | 2019-11-04 | 2023-04-04 | 锐新医药公司 | Ras抑制剂 |
| CR20230165A (es) | 2020-09-15 | 2023-06-02 | Revolution Medicines Inc | Derivados indólicos como inhibidores de ras en el tratamiento del cáncer |
| KR20240017811A (ko) | 2021-05-05 | 2024-02-08 | 레볼루션 메디슨즈, 인크. | 암의 치료를 위한 ras 억제제 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN115028681B (zh) * | 2022-08-11 | 2022-11-15 | 中国科学院微生物研究所 | 一种降解亲环素a的嵌合体化合物及其制备方法与应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
| AR006514A1 (es) | 1995-07-04 | 1999-09-08 | Sandoz Ag | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
| CA2611151A1 (en) | 2005-06-17 | 2006-12-28 | Novartis Ag | Use of sanglifehrin in hcv |
| CA2674296C (en) | 2007-01-04 | 2015-11-24 | Debiopharm Sa | Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy |
| CN101691575B (zh) * | 2008-09-24 | 2013-06-05 | 中国科学院上海有机化学研究所 | 一种萨菲菌素的生物合成基因簇 |
| CN102224242B (zh) | 2008-09-24 | 2014-09-24 | 中国科学院上海有机化学研究所 | 新基因簇 |
| WO2011098805A1 (en) * | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| CA2788761C (en) | 2010-02-09 | 2018-05-29 | Biotica Technology Limited | Sanglifehrin based compounds useful for treating viral infection caused by hcv, hbv or hiv |
| WO2011098808A1 (en) | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| BR112013015501A2 (pt) * | 2010-12-20 | 2017-05-16 | Neurovive Pharmaceutical Ab | composto, composição farmacêutica, métodos para tratamento de infecções virais e de distúrbios inflamatórios, e, processo para produzir uma sangliferrina mutassintética |
| JO3063B1 (ar) * | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | مركب مبتكر وطرق لانتاجه |
-
2012
- 2012-03-12 JO JOP/2012/0053A patent/JO3063B1/ar active
- 2012-03-28 AR ARP120101043A patent/AR085724A1/es unknown
- 2012-03-28 TW TW101110673A patent/TWI525098B/zh not_active IP Right Cessation
- 2012-03-29 KR KR1020137028095A patent/KR101911484B1/ko not_active Expired - Fee Related
- 2012-03-29 BR BR112013024974A patent/BR112013024974A2/pt not_active Application Discontinuation
- 2012-03-29 PH PH1/2013/502000A patent/PH12013502000B1/en unknown
- 2012-03-29 EA EA201391399A patent/EA023848B1/ru not_active IP Right Cessation
- 2012-03-29 PL PL12716538T patent/PL2691412T3/pl unknown
- 2012-03-29 ES ES12716538.9T patent/ES2533437T3/es active Active
- 2012-03-29 WO PCT/GB2012/050700 patent/WO2012131371A1/en active Application Filing
- 2012-03-29 EP EP12716538.9A patent/EP2691412B1/en active Active
- 2012-03-29 BR BR112013024965A patent/BR112013024965A2/pt not_active Application Discontinuation
- 2012-03-29 SI SI201230146T patent/SI2691413T1/sl unknown
- 2012-03-29 EA EA201391396A patent/EA023907B1/ru not_active IP Right Cessation
- 2012-03-29 UY UY0001033993A patent/UY33993A/es not_active Application Discontinuation
- 2012-03-29 CA CA2830827A patent/CA2830827C/en not_active Expired - Fee Related
- 2012-03-29 RS RS20150162A patent/RS53964B1/en unknown
- 2012-03-29 CN CN201611126823.4A patent/CN107417766A/zh active Pending
- 2012-03-29 JP JP2014501720A patent/JP6118793B2/ja active Active
- 2012-03-29 MY MYPI2013701789A patent/MY170618A/en unknown
- 2012-03-29 PL PL12716539T patent/PL2691413T3/pl unknown
- 2012-03-29 SG SG2013070974A patent/SG193569A1/en unknown
- 2012-03-29 KR KR1020137027773A patent/KR101868084B1/ko not_active Expired - Fee Related
- 2012-03-29 JP JP2014501719A patent/JP6118792B2/ja not_active Expired - Fee Related
- 2012-03-29 AU AU2012235961A patent/AU2012235961B2/en not_active Ceased
- 2012-03-29 US US14/006,341 patent/US9139613B2/en active Active
- 2012-03-29 CN CN201280026793.3A patent/CN103635484B/zh active Active
- 2012-03-29 EP EP12716539.7A patent/EP2691413B1/en active Active
- 2012-03-29 CA CA2830831A patent/CA2830831C/en not_active Expired - Fee Related
- 2012-03-29 MX MX2013011043A patent/MX345351B/es active IP Right Grant
- 2012-03-29 HR HRP20150187TT patent/HRP20150187T1/hr unknown
- 2012-03-29 ES ES12716539.7T patent/ES2533438T3/es active Active
- 2012-03-29 MY MYPI2013701788A patent/MY170637A/en unknown
- 2012-03-29 PT PT127165397T patent/PT2691413E/pt unknown
- 2012-03-29 MX MX2013011051A patent/MX345352B/es active IP Right Grant
- 2012-03-29 HR HRP20150184TT patent/HRP20150184T1/hr unknown
- 2012-03-29 AU AU2012235880A patent/AU2012235880B2/en not_active Ceased
- 2012-03-29 SI SI201230145T patent/SI2691412T1/sl unknown
- 2012-03-29 PT PT127165389T patent/PT2691412E/pt unknown
- 2012-03-29 DK DK12716538T patent/DK2691412T3/en active
- 2012-03-29 RS RS20150161A patent/RS53963B1/en unknown
- 2012-03-29 US US13/433,944 patent/US9090657B2/en active Active
- 2012-03-29 WO PCT/GB2012/050707 patent/WO2012131377A1/en active Application Filing
- 2012-03-29 SG SG2013070966A patent/SG193568A1/en unknown
- 2012-03-29 DK DK12716539T patent/DK2691413T3/en active
- 2012-03-29 PH PH1/2013/502016A patent/PH12013502016A1/en unknown
- 2012-03-29 CN CN201280026190.3A patent/CN103619869B/zh not_active Expired - Fee Related
-
2013
- 2013-09-17 IL IL228509A patent/IL228509B/en active IP Right Grant
- 2013-09-17 IL IL228508A patent/IL228508B/en active IP Right Grant
- 2013-09-23 ZA ZA2013/07149A patent/ZA201307149B/en unknown
- 2013-09-25 CL CL2013002739A patent/CL2013002739A1/es unknown
- 2013-09-25 CL CL2013002740A patent/CL2013002740A1/es unknown
- 2013-09-26 ZA ZA2013/07231A patent/ZA201307231B/en unknown
-
2015
- 2015-02-27 CY CY20151100207T patent/CY1116318T1/el unknown
- 2015-03-06 CY CY20151100236T patent/CY1116186T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014510746A5 (enrdf_load_stackoverflow) | ||
| EP3527573B9 (en) | Synthesis of polycyclic-carbamoylpyridone compounds | |
| JP6386171B2 (ja) | 新規なアミノアルキルベンゾチアゼピン誘導体及びその用途 | |
| JP2010523522A5 (enrdf_load_stackoverflow) | ||
| JP2015536940A (ja) | 抗ウイルス性ホスホネート類似体及びその製造方法 | |
| HRP20150184T1 (hr) | Makrocikliäśki spoj i postupci za njegovu proizvodnju | |
| JP2013518923A5 (enrdf_load_stackoverflow) | ||
| EP2321323B9 (fr) | Derives dimeriques d'artemisinine et application en therapie anticancereuse | |
| WO2007013086A1 (en) | Novel polymorphs of tenofovir disoproxil fumarate | |
| CN118480041A (zh) | 取代的多环化合物及其药物组合物和用途 | |
| WO2009074020A1 (en) | Alpha-amino-n-substituted amides, pharmaceutical composition containing them and uses thereof | |
| JP2009143931A (ja) | テトラゾリルベンゾピランの製法 | |
| JP2016503389A (ja) | （１ｓ，４ｓ，５ｓ）−４−ブロモ−６−オキサビシクロ［３．２．１］オクタン−７−オンの調製方法 | |
| CA2647163C (en) | Modified macrophage migration inhibitory factor inhibitors | |
| WO2016038560A1 (en) | Process for the preparation of enzalutamide | |
| RU2010134904A (ru) | Кристаллическая форма абакавира, которая, по существу, свободна от растворителя | |
| CN120424092B (zh) | 布尼亚病毒抑制剂及其制备方法和用途 | |
| JP5863846B2 (ja) | イリノテカンの製造方法 | |
| JP2021523187A (ja) | リナグリプチンおよびその塩の製造のための中間体およびプロセス | |
| CN110590768B (zh) | 杂环化合物、其组合物及其作为抗流感病毒药物的应用 | |
| WO2017009746A1 (en) | An improved process for the preparation of sofosbuvir | |
| Ye et al. | Studies on the asymmetric synthesis of pandamarilactonines: an unexpected syn-selective vinylogous Mannich reaction of N-tert-butanesulfinimines | |
| JP7233100B2 (ja) | 肝臓送達に基づく抗ｃ型肝炎プロドラッグであるヌクレオシド環状リン酸エステル化合物及びその使用 | |
| Therkelsen et al. | New emivirine (MKC-442) analogues containing a tetrahydronaphthalene at C-6 and their anti-HIV activity | |
| HK40044746A (en) | Synthesis of polycyclic-carbamoylpyridone compounds |